| [1] |
Teo ZL, Tham YC, Yu M, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta－analysis[J]. Ophthalmology, 2021, 128(11): 1580－1591.
|
| [2] |
刘涵，方晏红，张蓝月，等. 血脂异常与糖尿病视网膜病变的相关性研究进展[J]. 中华眼科医学杂志(电子版)，2023，13(5)：301－305.
|
| [3] |
Nawaz IM, Rezzola S, Cancarini A, et al. Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications[J]. Prog Retin Eye Res, 2019, 72: 100756.
|
| [5] |
Arrigo A, Aragona E, Bandello F. VEGF－targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy[J]. Ann Med, 2022, 54(1): 1089－1111.
|
|
Wang X, Bove AM, Simone G, et al. Molecular Bases of VEGFR－2－Mediated Physiological Function and Pathological Role[J]．Front Cell Dev Biol, 2020, 8: 599281.
|
| [6] |
Bucolo C, Barbieri A, ViganòI, et al. Short－and Long－Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy[J]. Front Pharmacol, 2021, 12: 707909.
|
| [7] |
Hirano T, Toriyama Y, Iesato Y, et al. Changes in plasma vascular endothelial growth factor level after intravitreal injection of Bevacizumab, Aflibercept, or Ranibizumab for diabetic macular edema[J]. Retina, 2018, 38: 1801－1808.
|
| [8] |
Ahuja S, Saxena S, AkdumanL, et al. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy[J]. Int J Retina Vitreous.2019, 5: 29.
|
| [9] |
Abu－Yaghi NE, AbuTarboush NM, Abojaradeh AM, et al. Relationship between Serum Vascular Endothelial Growth Factor Levels and StAGE of Diabetic Retinopathy and Other Biomarkers[J]. J Ophthalmol, 2020: 1－7..
|
| [10] |
Majidreza S, Alizadeh M, Saeid A. The tear VEGF and IGFBP3 in healthy and diabetic retinopathy[J]. International Journal of Diabetes in Developing Countries, 2019, 40: 93－98.
|
| [11] |
Midena E, Frizziero L, Midena G, et al. Intraocular fluid biomarkers(liquid biopsy) in human diabetic retinopathy[J]．Graefes Arch Clin Exp Ophthalmol.2021, 259(12): 3549－3560.
|
| [12] |
Wang JY, Kwon JS, Hsu SM, et al. Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform[J]. Lab Chip, 2020, 20(2): 356－362.
|
| [13] |
Bonfiglio V, Platania CBM, Lazzara F, et al. TGF－β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti－VEGF Therapy[J]．Int J Mol Sci, 2020, 21(24): 9558.
|
| [14] |
Karbasforooshan H, Karimi G. The role of SIRT1 in diabetic retinopathy. Biomed Pharmacother[J]. 2018, 97: 190－194.
|
| [15] |
Maisto R, Trotta MC, Petrillo F, et al. Resolvin D1 Modulates the Intracellular VEGF－Related miRNAs of Retinal Photoreceptors Challenged With High Glucose[J]. Front Pharmacol, 2020, 11: 235.
|
| [16] |
张浩，方新梅，张玛丽，等. 微小核糖核酸7641/沉默信息调节因子1途径参与高糖诱导的人视网膜微血管内皮细胞损伤的研究[J]．中国糖尿病杂志，2023，31(11)：845－849.
|
| [17] |
Shan L, Zhang H, Han Y, et al. Expression and mechanism of microRNA 195 in diabetic retinopathy[J]. Endocr J, 2022, 69(5): 529－537.
|
| [18] |
Pan Q, Gao Z, Zhu C, et al. Overexpression of histone deacetylase SIRT1 exerts an antiangiogenic role in diabetic retinopathy via miR－20a elevation and YAP/HIF1α/VEGFA depletion[J]. Am J Physiol Endocrinol Metab, 2020, 319(5): 932－943.
|
| [19] |
Ko GY, Yu F, Bayless KJ, et al. MicroRNA－150 (miR－150) and Diabetic Retinopathy: Is miR－150 Only a Biomarker or Does It Contribute to Disease Progression? [J]. Int J Mol Sci, 2022, 23(20): 12099.
|
| [20] |
Yin C, Lin X, Sun Y, et al. Dysregulation of miR－210 is involved in the development of diabetic retinopathy and serves a regulatory role in retinal vascular endothelial cell proliferation[J]. Eur J Med Res, 2020, 25(1): 20.
|
| [21] |
Liang Z, Gao KP, Wang YX, et al. RNA sequencing identified specific circulating miRNA biomarkers for early detection of diabetes retinopathy[J]. Am J Physiol Endocrinol Metab, 2018, 315(3): 374－385.
|
| [22] |
Santovito D, Toto L, De Nardis V, et al. Plasma microRNA signature associated with retinopathy in patients with type 2 diabetes[J]. Sci Rep, 2021, 11(1): 4136.
|
| [23] |
Kot A, Kaczmarek R. Exosomal miRNA Profiling in Vitreous Humor in Proliferative Diabetic Retinopathy[J]. Cells, 2022, 12(1): 123.
|
| [24] |
Saleh AA, El－Hefnawy SM, Kasemy ZA, et al. Mi－RNA－93 and Mi－RNA－152 in the Diagnosis of Type 2 Diabetes and Diabetic Retinopathy[J]．Br J Biomed Sci, 2022, 79: 10192.
|
| [25] |
Ma L, Wen Y, Li Z, et al. Circulating MicroRNAs as Potential Diagnostic Biomarkers for Diabetic Retinopathy: A Meta－Analysis[J]. Front Endocrinol (Lausanne), 2022, 13: 929924.
|
| [26] |
Jenkins HN, Rivera－Gonzalez O, Gibert Y, et al. Endothelin－1 in the pathophysiology of obesity and insulin resistance[J]. Obes Rev, 2020, 21(12): 13086.
|
| [27] |
Kostov K. The Causal Relationship between Endothelin－1 and Hypertension: Focusing on Endothelial Dysfunction, Arterial Stiffness, Vascular Remodeling, and Blood Pressure Regulation[J]. Life (Basel), 2021, 11(9): 986.
|
| [28] |
Cheung SS, Leung JW, Lam AK, et al. Selective over－expression of endothelin－1 in endothelial cells exacerbates inner retinal edema and neuronal death in ischemic retina[J]．PLoS One, 2011, 6(10): 26184.
|
| [29] |
Chen YL, Rosa RH, Kuo L, et al. Hyperglycemia Augments Endothelin－1－Induced Constriction of Human Retinal Venules[J]. Transl Vis Sci Technol, 2020, 9(9): 1.
|
| [30] |
Bogdanov P, Simó－Servat O, Sampedro J, et al. Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes[J]. Int J Mol Sc i, 2018, 19(11): 3578.
|
| [31] |
Kang HM, Hasanuzzaman M, Kim SW, et al.Elevated aqueous endothelin－1 concentrations in advanced diabetic retinopathy[J]. PLoS One, 2022, 17(5): 0268353.
|
| [32] |
Alrashdi SF, Deliyanti D, Wilkinson－Berka JL. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats[J]. Exp Eye Res, 2018, 176: 1－9.
|
| [33] |
Shen CY, Lu CH, Wu CH, et al. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)－Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE－Related Diseases[J]. Molecules, 2020, 25(23): 5591.
|
| [34] |
Pal R, Bhadada SK. AGE accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review[J]. Bone, 2023, 176: 116884.
|
| [35] |
Hanaguri J, Yokota H, Kushiyama A, et al. Beneficial Effect of Long－Term Administration of Supplement With Trapa BispinosaRoxb. and Lutein on Retinal Neurovascular Coupling in Type 2 Diabetic Mice[J]. Front Physiol, 2022, 13: 788034.
|
| [36] |
Zhang Q, Wang Y, Fu L. Dietary advanced glycation end－products: Perspectives linking food processing with health implications[J]. Compr Rev Food Sci Food Saf, 2020, 19(5): 2559－2587.
|
| [37] |
Chung YR, Choi JA, Koh JY, et al. Ursodeoxycholic Acid Attenuates Endoplasmic Reticulum Stress－Related Retinal Pericyte Loss in Streptozotocin－Induced Diabetic Mice[J]. J Diabetes Res, 2017；2017: 1－10.
|
| [38] |
Osawa S, Katakami N, SatoI, et al. Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes[J]. J Diabetes Complications, 2018, 32(9): 839－844.
|
| [39] |
Sirman YV, SavytskyiI V. Study of endothelial dysfunction and asymmetric dimethylarginine levels[J]. Journal of Education Health and Sport, 2019, 9: 395－412.
|
| [40] |
Peters KS, Rivera E, Warden C, et al. Plasma Arginine and Citrulline are Elevated in Diabetic Retinopathy[J]. Am J Ophthalmol, 2022, 235: 154－162.
|
| [41] |
Celik M, Cerrah S, Arabul M, et al. Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients[J]. J Diabetes Res, 2014, 2014: 1－6.
|
| [42] |
Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2023, 14: 1183586.
|
| [43] |
Wieczór R, Wieczór AM, Kulwas A, et al. ADMA (asymmetric dimethylarginine)and angiogenic potential in patients with type 2 diabetes and prediabetes[J]. Exp Biol Med (Maywood), 2021, 246(2): 153－162.
|
| [44] |
Du MR, Yan L, Li NS, et al. Asymmetric dimethylarginine contributes to retinal neovascularization of diabetic retinopathy through EphrinB2 pathway[J]. VasculPharmacol, 2018, 108: 46－56.
|
| [45] |
Aydoĝan S, Dilli D, Kabata EU, et al. The Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Insulin－Like Growth Factor－1 in Preterms with Retinopathy of Prematurity[J]. Fetal Pediatr Pathol, 2022 , 41(4): 634－639.
|
| [46] |
Cvitkovic K, Sesar A, Sesar I, et al. Concentrations of Selected Cytokines and Vascular Endothelial Growth Factor in Aqueous Humor and Serum of Diabetic Patients[J]. Semin Ophthalmol, 2020, 35(2): 126－133.
|
| [47] |
Batsos G, Christodoulou E, Christou EE, et al. Vitreous inflammatory and angiogenic factors on patients with proliferative diabetic retinopathy or diabetic macular edema: the role of Lipocalin2[J]. BMC Ophthalmol, 2022 , 22(1): 496.
|
| [48] |
Obadâ O, Pantalon AD, Rusu－Zota G, et al. Aqueous Humor Cytokines in Non－Proliferative Diabetic Retinopathy[J]. Medicina (Kaunas), 2022, 58(7): 909.
|
| [49] |
Tan W, Zou JL, Yoshida S, et al. Increased vitreal levels of interleukin－10 in diabetic retinopathy: a Meta－analysis. Int J Ophthalmol, 2020, 13(9): 1477－1483.
|
| [50] |
Zhang H, Liang L, Huang R, et al. Comparison of inflammatory cytokines levels in the aqueous humor with diabetic retinopathy[J]. Int Ophthalmol, 2020, 40(10): 2763－2769.
|
| [51] |
Zeng L, Ma W, Shi L, et al. Poly(lactic－co－glycolic acid) nanoparticle－mediated interleukin－12 delivery for the treatment of diabetic retinopathy[J]. Int J Nanomedicine, 2019, 14: 6357－6369.
|
| [52] |
Wang Y, Zhai WL, Yang YW. Association between NDRG2/IL－6/STAT3 signaling pathway and diabetic retinopathy in rats[J]. Eur Rev Med Pharmacol Sci, 2020 , 24(7): 3476－3484.
|
| [53] |
Stahel M, Becker M, Graf N, et al. SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open－Label Study Using Canakinumab[J]. Retina, 2016 , 36(2): 385－91.
|
| [54] |
齐丽莉，马清光，杨艳秋等．β2－MG、TNF－α联合检测在2型糖尿病视网膜病变早期诊断中的临床价值[J]. 中国老年学杂志，2023，43(13)：3159－3162.
|
| [55] |
Yang F, Zhang H, Yu X, et al. TNFAIP8 overexpression aggravates retinal pathophysiological features of diabetic retinopathy[J]. Exp Eye Res, 2023, 234: 109572.
|
| [56] |
Li L, Wu X, He L, et al. Serum levels of SOCS6 are decreased in diabetic retinopathy and are related to severity of the disease[J]. Adv Clin Exp Med, 2023, 32(8): 873－880.
|
| [57] |
Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double－blind, placebo－controlled, crossover, 32－week study[J]. Diabetes Care, 2010, 33(7): 1523－1528.
|